Aldosterone blockade in chronic kidney disease: Can it improve outcome?

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 444-449

  Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

eplerenone; mineralocorticoid receptor; outcome trials; spironolactone

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO; SPIRONOLACTONE;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; HUMAN; HYPERKALEMIA; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; PROTEIN-SERINE-THREONINE KINASES; PROTEINURIA; SODIUM;

EID: 77955926343     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833ce6d5     Document Type: Review

References (65)

1. United States Renal Data Systems Annual Data Report. 2008 (Accessed at www.usrds.org.).
2. Brenner BM, Cooper ME, De ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
3. Rodby RA, Rohde RD, Clarke WR, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000; 15:487-497.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
5. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
6. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multi-factorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
7. Investigators O. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
8. Bomback AS, Toto R. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens 2009; 22:1032-1040.
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-2032.
10. Teiwes J, Toto RD. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens 2007; 20:109-117.
11. Fiebeler A, Muller DN, Shagdarsuren E, Luft FC. Aldosterone, mineralocorti-coid receptors, and vascular inflammation. Curr Opin Nephrol Hypertens 2007; 16:134-142.
12. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 2008; 17:174-180.
13. Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1685-1691.
14. Yamada M, Kushibiki M, Osanai T, et al. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res 2008; 79:169-178.
15. Stas S, Whaley-Connell A, Habibi J, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007; 148:3773-3780.
16. Michea L, Villagran A, Urzua A, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 2008; 52:295-300.
17. Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48:165-171.
18. Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009; 24:73-84.
19. Fan YY, BabaR, NagaiY, et al. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effectsof an ultrahigh dose ofolmesartan. Hypertens Res 2006; 29:169-178.
20. Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007; 8:118-126.
21. Takeda Y. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hyper-tens Res 2009; 32:321-324.
22. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008; 12:233-242.
23. Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49:355-364.
24. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51:161-167.
25. Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralo-corticoid receptor: role of oxidative stress. Hypertension 2007; 50:877-883.
26. Bayorh MA, Ganafa AA, Emmett N, et al. Alterations in aldosterone and angiotensin II levels in salt-induced hypertension. Clin Exp Hypertens 2005; 27:355-367.
27. Bayorh MA, Mann G, Walton M, Eatman D. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats. Clin Exp Hypertens 2006; 28:121-132.
28. Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res 2009; 32:649-657.
29. MatsuiH,AndoK,KawarazakiH,etal.Saltexcess causes leftventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008; 52:287-294.
30. VirdisA,Neves MF, Amiri F, etal. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40:504-510.
31. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioac-tivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101:594-597.
32. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91:2214-2217.
33. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43:518-524.
34. Goodfriend TL, Ball DL, Egan BM, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43:358-363.
35. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
36. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
37. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551.
38. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. J Am Med Assoc 2002; 288:2421-2431.
39. Kent DM, Jafar TH, Hayward RA, et al. or the AIRPD Study Group. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18:1959-1965.
40. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
41. De ZD, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
42. De Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
43. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51:199-211.
44. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28:2106-2112.
45. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70:536-542.
46. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1:940-951.
47. Van Den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24:2285-2292.
48. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1:256-262.
49. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20:2641-2650.
50. Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009; 297:F1381-F1390.
51. Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14:1370-1376.
52. Nishiyama A, Kobori H, Konishi Y, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 332:1072-1080.
53. Xu B, English JM, Wilsbacher JL, et al. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 2000; 275:16795-16801.
54. Xu BE, Stippec S, Lenertz L, et al. WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J Biol Chem 2004; 279:7826-7831.
55. Lenertz LY, Lee BH, Min X, et al. Properties of WNK1 and implications for other family members. J Biol Chem 2005; 280:26653-26658.
56. Zagorska A, Pozo-Guisado E, Boudeau J, et al. Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol 2007; 176:89-100.
57. Delaloy C, Lu J, Houot AM, et al. Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 2003; 23:9208-9221.
58. O'Reilly M, Marshall E, Speirs HJ, Brown RW. WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. J Am Soc Nephrol 2003; 14:2447-2456.
59. Gordon RD. The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon's syndrome. AustNZJ Med 1986; 16:183-184.
60. Lazrak A, Liu Z, Huang CL. Antagonistic regulation of ROMK by long and kidney-specific WNK1 isoforms. Proc Natl Acad Sci\USA2006; 103:1615-1620.
61. Wade JB, Fang L, Liu J, et al. WNK1 kinase isoform switch regulates renal potassium excretion. Proc Natl Acad Sci\USA 2006; 103:8558-8563.
62. Huang CL, Kuo E, Toto RD. WNK kinases and essential hypertension. Curr Opin Nephrol Hypertens 2008; 17:133-137.
63. Sohara E TR, Akihtio O, Eriko O, Sasaki S, Uchida S. Novel Insulin-WNK4-NCC phosphorylation cascade is involved in pathogenesis of PHA II caused by WNK4 R1185C mutation [abstract]. American Society of Nephrology Annual Meeting 2009 2009:F-FC279.
64. Ellison D, Oyama T, Yang CL, Rogers S, Beard D, Komers R. Altered WNK4/NCC signaling in a rat model of insulin resistance [abstract]. American Society of Nephrology Annual Meeting 2009.
65. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418-424.